Brief: Zai Lab To Present Data From Phase 1 Trial Of ZL-1310, For DLL3+ Solid Tumors
Oct 9 (Reuters) - Zai Lab Ltd 9688.HK :
* ZAI LAB TO PRESENT DATA FROM PHASE 1 TRIAL OF ZL-1310, ITS
INVESTIGATIONAL ANTIBODY-DRUG CONJUGATE (ADC) FOR DLL3+ SOLID
TUMORS, AT EORTC-NCI-AACR SYMPOSIUM (ENA) 2024
* ZAI LAB LTD - TO PRESENT PHASE 1 DATA OF ZL-1310 AT ENA
2024
Source text for Eikon: ID:nBw1DpNT9a
Further company coverage: 9688.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zai Lab
See all newsBrief: Zai Lab Says ZL-1503 Was Well Tolerated With No Serious Adverse Events
Brief: Zai Lab Agrees To Issue To Investors Aggregate Of 11.3 Million ADSs
Zai Lab's Hong Kong shares hit three-month high on quarterly revenue beat
Brief: U.S. FDA Grants Orphan Drug Designation To Zai Lab’S Dll3-Targeting Adc Zocilurtatug Pelitecan (Zoci) For The Treatment Of Neuroendocrine Carcinomas (Necs)
Brief: Goldman Sachs Group's Long Position In Zai Lab Decreases On May 14, HKEX Filing Shows